Nuzenio

Tasrif Pharmaceutical

Tasrif Pharmaceutical news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Tasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms - Manufacturing ChemistManufacturing Chemist · Tue, 04 Aug 2026 12:14:55 GMTTasrif secures second US patent for CD155-targeting antibodies as anti-TIGIT field contracts - AllSciAllSci · Wed, 29 Jul 2026 14:10:13 GMTTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155) - Yahoo FinanceYahoo Finance · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Tue, 04 Aug 2026 12:14:55 GMTTasrif Pharmaceutical granted second US patent for CD155-targeting antibody developed with Abzena's humanisation and immunogenicity platforms - Manufacturing Chemist
Wed, 29 Jul 2026 14:10:13 GMTTasrif secures second US patent for CD155-targeting antibodies as anti-TIGIT field contracts - AllSci
Wed, 29 Jul 2026 07:00:00 GMTTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155) - Yahoo Finance

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tasrif Pharmaceutical.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.